{"entity":{"type":"insider","cik":"0001565099","url":"/insider/0001565099","json_url":"/insider/0001565099.json","name":"Deerfield Special Situations International Master Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":72,"n_filings":9,"first":"2014-02-04","last":"2015-01-05","span_basis":"filed_date"},"name_variants":[{"name":"Deerfield Special Situations International Master Fund, L.P.","source":"filing","n_filings":9,"first_seen":"2014-02-04","last_seen":"2015-01-05"}],"transactions":[{"id":8480899,"accession":"0001193805-15-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-15-000002","line_url":"/filing/0001193805-15-000002#line-2","is_derivative":false,"issuer_cik":"0000764579","issuer_name":"CAS MEDICAL SYSTEMS INC","issuer_ticker":"CASM","issuer_name_source":null,"issuer_url":"/issuer/0000764579","owner_cik":null,"owner_name":"Deerfield Special Situations Fund, L.P.; Flynn James E; DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.","owner_display_name":"Deerfield Special Situations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1443200.0,"shares_display":"1,443,200","price_per_share":1.65,"price_display":"1.65","price_state":"stated","total_value":2381280.0,"total_display":"2,381,280.00","total_whole":"2,381,280","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-01","filed_date":"2015-01-05","scope":"insider"},{"id":8480894,"accession":"0001193805-15-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-15-000002","line_url":"/filing/0001193805-15-000002#line-1","is_derivative":false,"issuer_cik":"0000764579","issuer_name":"CAS MEDICAL SYSTEMS INC","issuer_ticker":"CASM","issuer_name_source":null,"issuer_url":"/issuer/0000764579","owner_cik":null,"owner_name":"Deerfield Special Situations Fund, L.P.; Flynn James E; DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.","owner_display_name":"Deerfield Special Situations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1443200.0,"shares_display":"1,443,200","price_per_share":1.65,"price_display":"1.65","price_state":"stated","total_value":2381280.0,"total_display":"2,381,280.00","total_whole":"2,381,280","shares_owned_after":3200000.0,"shares_owned_after_display":"3,200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-01","filed_date":"2015-01-05","scope":"insider"},{"id":6698591,"accession":"0001193805-14-002137","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-14-002137","line_url":"/filing/0001193805-14-002137","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund II, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Private Design International II, L.P.; DEERFIELD MANAGEMENT CO; Deerfield Special Situations International Master Fund, L.P.; Flynn James E","owner_display_name":"Deerfield Private Design Fund II, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":214164.0,"shares_display":"214,164","price_per_share":9.050792850338993,"price_display":"9.05","price_state":"stated","total_value":1938354.0,"total_display":"1,938,354.00","total_whole":"1,938,354","shares_owned_after":33600.0,"shares_owned_after_display":"33,600","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-11-07","filed_date":"2014-11-10","scope":"insider","n_lines":3},{"id":6521200,"accession":"0001193805-14-002017","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001193805-14-002017","line_url":"/filing/0001193805-14-002017","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"PROTEON THERAPEUTICS INC","issuer_ticker":"PRTO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; DEERFIELD MANAGEMENT CO; Flynn James E; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.","owner_display_name":"Deerfield Mgmt III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":691713.0,"shares_display":"691,713","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":6917130.0,"total_display":"6,917,130.00","total_whole":"6,917,130","shares_owned_after":876391.0,"shares_owned_after_display":"876,391","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-10-27","filed_date":"2014-10-27","scope":"insider","n_lines":11},{"id":6491090,"accession":"0001193805-14-001973","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001193805-14-001973","line_url":"/filing/0001193805-14-001973#line-13","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Flynn James E; Deerfield Private Design International II, L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Private Design Fund II, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51449.0,"shares_display":"51,449","price_per_share":10.01,"price_display":"10.01","price_state":"stated","total_value":515004.49,"total_display":"515,004.49","total_whole":"515,004","shares_owned_after":214164.0,"shares_owned_after_display":"214,164","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-10-15","filed_date":"2014-10-15","scope":"insider"},{"id":6491086,"accession":"0001193805-14-001973","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001193805-14-001973","line_url":"/filing/0001193805-14-001973","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Flynn James E; Deerfield Private Design International II, L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Private Design Fund II, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36115.0,"shares_display":"36,115","price_per_share":11.02,"price_display":"11.02","price_state":"stated","total_value":397987.3,"total_display":"397,987.30","total_whole":"397,987","shares_owned_after":946077.0,"shares_owned_after_display":"946,077","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-10-14","filed_date":"2014-10-15","scope":"insider","n_lines":4},{"id":6491079,"accession":"0001193805-14-001973","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-14-001973","line_url":"/filing/0001193805-14-001973","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Flynn James E; Deerfield Private Design International II, L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Private Design Fund II, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30214.0,"shares_display":"30,214","price_per_share":12.132297213212418,"price_display":"12.13","price_state":"stated","total_value":366565.228,"total_display":"366,565.23","total_whole":"366,565","shares_owned_after":960787.0,"shares_owned_after_display":"960,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-10-10","filed_date":"2014-10-15","scope":"insider","n_lines":8},{"id":6554315,"accession":"0001193805-14-001626","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-14-001626","line_url":"/filing/0001193805-14-001626","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Special Situations International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD PARTNERS, LP; Flynn James E; DEERFIELD MANAGEMENT CO; Deerfield Mgmt L.P.; Deerfield International Master Fund, L.P.","owner_display_name":"Deerfield Special Situations International Master Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1089656.0,"shares_display":"1,089,656","price_per_share":13.006408260955752,"price_display":"13.01","price_state":"stated","total_value":14172510.8,"total_display":"14,172,510.80","total_whole":"14,172,511","shares_owned_after":586651.0,"shares_owned_after_display":"586,651","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-06","filed_date":"2014-08-06","scope":"insider","n_lines":6},{"id":6941879,"accession":"0001193805-14-001617","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-24","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":219864.0,"shares_display":"219,864","price_per_share":26.42,"price_display":"26.42","price_state":"stated","total_value":5808806.88,"total_display":"5,808,806.88","total_whole":"5,808,807","shares_owned_after":505636.0,"shares_owned_after_display":"505,636","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941872,"accession":"0001193805-14-001617","txn_seq":23,"anchor":"line-23","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-23","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":201972.0,"shares_display":"201,972","price_per_share":25.41,"price_display":"25.41","price_state":"stated","total_value":5132108.52,"total_display":"5,132,108.52","total_whole":"5,132,109","shares_owned_after":257272.0,"shares_owned_after_display":"257,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941869,"accession":"0001193805-14-001617","txn_seq":22,"anchor":"line-22","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-22","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":177700.0,"shares_display":"177,700","price_per_share":26.42,"price_display":"26.42","price_state":"stated","total_value":4694834.0,"total_display":"4,694,834.00","total_whole":"4,694,834","shares_owned_after":408700.0,"shares_owned_after_display":"408,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941866,"accession":"0001193805-14-001617","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-21","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":163300.0,"shares_display":"163,300","price_per_share":25.41,"price_display":"25.41","price_state":"stated","total_value":4149453.0,"total_display":"4,149,453.00","total_whole":"4,149,453","shares_owned_after":208000.0,"shares_owned_after_display":"208,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941862,"accession":"0001193805-14-001617","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-20","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":123077.0,"shares_display":"123,077","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":2092309.0,"total_display":"2,092,309.00","total_whole":"2,092,309","shares_owned_after":654285.0,"shares_owned_after_display":"654,285","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941860,"accession":"0001193805-14-001617","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-19","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55300.0,"shares_display":"55,300","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":940100.0,"total_display":"940,100.00","total_whole":"940,100","shares_owned_after":55300.0,"shares_owned_after_display":"55,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941855,"accession":"0001193805-14-001617","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-18","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":49981.0,"shares_display":"49,981","price_per_share":26.35,"price_display":"26.35","price_state":"stated","total_value":1316999.35,"total_display":"1,316,999.35","total_whole":"1,316,999","shares_owned_after":595617.0,"shares_owned_after_display":"595,617","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941852,"accession":"0001193805-14-001617","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-17","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":44700.0,"shares_display":"44,700","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":759900.0,"total_display":"759,900.00","total_whole":"759,900","shares_owned_after":44700.0,"shares_owned_after_display":"44,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941848,"accession":"0001193805-14-001617","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-16","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":42700.0,"shares_display":"42,700","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":725900.0,"total_display":"725,900.00","total_whole":"725,900","shares_owned_after":227294.0,"shares_owned_after_display":"227,294","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941844,"accession":"0001193805-14-001617","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-15","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40400.0,"shares_display":"40,400","price_per_share":26.35,"price_display":"26.35","price_state":"stated","total_value":1064540.0,"total_display":"1,064,540.00","total_whole":"1,064,540","shares_owned_after":481600.0,"shares_owned_after_display":"481,600","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941841,"accession":"0001193805-14-001617","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-14","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34223.0,"shares_display":"34,223","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":581791.0,"total_display":"581,791.00","total_whole":"581,791","shares_owned_after":181633.0,"shares_owned_after_display":"181,633","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941837,"accession":"0001193805-14-001617","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-13","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31650.0,"shares_display":"31,650","price_per_share":24.57,"price_display":"24.57","price_state":"stated","total_value":777640.5,"total_display":"777,640.50","total_whole":"777,641","shares_owned_after":627267.0,"shares_owned_after_display":"627,267","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941834,"accession":"0001193805-14-001617","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-12","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27600.0,"shares_display":"27,600","price_per_share":26.14,"price_display":"26.14","price_state":"stated","total_value":721464.0,"total_display":"721,464.00","total_whole":"721,464","shares_owned_after":545636.0,"shares_owned_after_display":"545,636","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941828,"accession":"0001193805-14-001617","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-11","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25600.0,"shares_display":"25,600","price_per_share":24.57,"price_display":"24.57","price_state":"stated","total_value":628992.0,"total_display":"628,992.00","total_whole":"628,992","shares_owned_after":507200.0,"shares_owned_after_display":"507,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"},{"id":6941822,"accession":"0001193805-14-001617","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001193805-14-001617","line_url":"/filing/0001193805-14-001617#line-10","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Avalanche Biotechnologies, Inc.","issuer_ticker":"AAVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO; Flynn James E; DEERFIELD PARTNERS, LP; Deerfield Mgmt L.P.; Deerfield Special Situations International Master Fund, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield International Master Fund, L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22400.0,"shares_display":"22,400","price_per_share":26.14,"price_display":"26.14","price_state":"stated","total_value":585536.0,"total_display":"585,536.00","total_whole":"585,536","shares_owned_after":441200.0,"shares_owned_after_display":"441,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-05","filed_date":"2014-08-05","scope":"insider"}],"collapsed":true,"next_cursor":"2014-08-05|6941822","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000764579","name":"CAS MEDICAL SYSTEMS INC","url":"/issuer/0000764579","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-01-05","last_seen":"2015-01-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001399529","name":"Dicerna Pharmaceuticals Inc","url":"/issuer/0001399529","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2014-02-04","last_seen":"2014-11-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001359931","name":"PROTEON THERAPEUTICS INC","url":"/issuer/0001359931","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-10-27","last_seen":"2014-10-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001581720","name":"Loxo Oncology, Inc.","url":"/issuer/0001581720","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-08-06","last_seen":"2014-08-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001501756","name":"Avalanche Biotechnologies, Inc.","url":"/issuer/0001501756","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-08-05","last_seen":"2014-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001432732","name":"TriVascular Technologies, Inc.","url":"/issuer/0001432732","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-04-22","last_seen":"2014-04-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001454189","name":"Auspex Pharmaceuticals, Inc.","url":"/issuer/0001454189","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-02-11","last_seen":"2014-02-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001565099","retrieved_at":"2026-08-23T09:25:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}